Sanofi Reports the P-II Study Data of Riliprubart to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Shots:
- The P-II trial assesses riliprubart for the treatment of CIDP in patients who are SoC-treated (cohort 1), SoC-refractory (cohort 2) & SoC-naïve (cohort 3) for 24wks. (part A) with an optional treatment expansion for 52wks. (part B)
- Study showed improved or stable responses in 87% SOC-treated (52% had greater improvement vs SoC), 89% SOC-refractory (50% had improvement) & 92% SOC-naïve patients at 24wks. with 72%, 89% & 71%, respectively, remaining on response for another 1yr.
- Sanofi has begun 2 P-III trials to find the safety & efficacy of riliprubart with MOBILIZE study for SoC refractory CIDP patients & VITALIZE study for CIDP adults on maintenance therapy with immunoglobulin (IV)
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
